NASDAQ:EPIX ESSA Pharma Q3 2024 Earnings Report $0.21 -0.01 (-5.20%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$0.20 0.00 (-1.02%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast ESSA Pharma EPS ResultsActual EPS-$0.16Consensus EPS -$0.26Beat/MissBeat by +$0.10One Year Ago EPSN/AESSA Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AESSA Pharma Announcement DetailsQuarterQ3 2024Date8/5/2024TimeBefore Market OpensConference Call DateMonday, August 5, 2024Conference Call Time7:00AM ETUpcoming EarningsESSA Pharma's Q4 2025 earnings is scheduled for Tuesday, December 16, 2025, with a conference call scheduled on Friday, December 12, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) ESSA Pharma Earnings HeadlinesESSA Pharma Inc. (EPIX) Shareholder/Analyst Call Prepared Remarks TranscriptOctober 3 at 7:02 PM | seekingalpha.comEssa Pharma provides update on combination agreement with XenoOctober 1 at 10:38 AM | msn.comThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he’s kneecapped the Federal Reserve…October 4 at 2:00 AM | Banyan Hill Publishing (Ad)ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim OrderSeptember 30, 2025 | prnewswire.comESSA Pharma (NASDAQ:EPIX) & Nature's Sunshine Products (NASDAQ:NATR) Critical SurveySeptember 28, 2025 | americanbankingnews.comEssa Pharma amends business combination agreement with XenoTherapeuticsSeptember 24, 2025 | msn.comSee More ESSA Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ESSA Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ESSA Pharma and other key companies, straight to your email. Email Address About ESSA PharmaESSA Pharma (NASDAQ:EPIX) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies that target KCNQ potassium ion channels, which play a critical role in the regulation of neuronal excitability. The company’s research focuses on rare neurological and neurodevelopmental disorders driven by dysfunction in these channels. By leveraging proprietary small-molecule chemistry, ESSA Pharma aims to address underlying disease mechanisms rather than merely treating symptoms. The company’s lead candidate, EPI-589, is an orally delivered small molecule designed to upregulate KCNQ channel activity. EPI-589 is currently being evaluated in clinical trials for Temple-Baraitser syndrome and KCNQ2 developmental and epileptic encephalopathy, two ultra-rare genetic conditions characterized by severe seizures, developmental delays and motor impairments. In addition to EPI-589, ESSA Pharma maintains a preclinical pipeline of novel modulators intended to expand its portfolio into other disorders linked to KCNQ dysfunction. Founded in Canada and headquartered in Vancouver, ESSA Pharma conducts its research and clinical programs across North America and Europe. The company collaborates with leading academic institutions and patient advocacy groups to design trials that address the unique challenges of rare disease studies, including small patient populations and high unmet medical need. ESSA Pharma is led by a management team with deep expertise in neuroscience drug development, translational research and regulatory strategy. The company is publicly traded on the Nasdaq Stock Market under the ticker symbol EPIX and is committed to advancing precision therapies that have the potential to transform outcomes for patients living with rare neurological disorders.View ESSA Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)BlackRock (10/14/2025)ASML (10/15/2025)Kinder Morgan (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
